REPL News and Press, Replimune Group Inc. From 02/08/24

2024-02-08 17:13:43 ET More on Replimune Group Replimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancer Replimune shares crash as skin cancer candidate fails trial Seeking Alpha’s Quant Rating on Replimune Group Read the full article ...

Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability of response Centrally reviewed 12-month primary analysis data from IGNYTE trial of RP1 in anti-PD1 failed melanoma and biologics licen...

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

2024-01-23 13:22:24 ET Summary Replimune Group is developing virus-based treatments for solid tumors, particularly skin cancer. The company's RP1 treatment did not show significant improvement in response rates compared to standard care in a phase 1/2 study, though there is a sign...

2024-01-21 17:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-13 12:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets appear to have...

2024-01-11 13:08:57 ET More on Atreca, Sera Prognostics, etc. Sera Prognostics: The Pregnancy Company On A Hot Streak Sera Prognostics, Inc (SERA) Q3 2023 Earnings Call Transcript Biggest stock movers today: Google, AMD, GameStop, C3.AI, Chewy and more Sera P...

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at ...

2023-12-24 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-05 12:36:51 ET More on Mid-day movers stocks. Meiwu technology company limited received nasdaq delisting determination Seeking Alpha’s Quant Rating on NuZee, Inc. Historical earnings data for NuZee, Inc. Financial information for NuZee, Inc. ...